|
Neuren is committed to seeking partnerships with larger companies with the resources and experience to manage large-scale clinical trials and achieve product approval and commercialisation. Due to its extensive pipeline, Neuren is also seeking out-licensing opportunities for its preclinical drug candidates, including:
|
- NNZ-2566 (oral) – targeting sub-acute brain disease (e.g. stroke recovery)
- NNZ-2591 – targeting Parkinson’s disease dementia
- NNZ-8000 – targeting major cancers
- NNZ-3600 – targeting growth hormone deficiency and obesity
|
|
|
